JP4780885B2 - 正常細胞を化学療法剤の細胞毒性から保護するための方法 - Google Patents

正常細胞を化学療法剤の細胞毒性から保護するための方法 Download PDF

Info

Publication number
JP4780885B2
JP4780885B2 JP2001529435A JP2001529435A JP4780885B2 JP 4780885 B2 JP4780885 B2 JP 4780885B2 JP 2001529435 A JP2001529435 A JP 2001529435A JP 2001529435 A JP2001529435 A JP 2001529435A JP 4780885 B2 JP4780885 B2 JP 4780885B2
Authority
JP
Japan
Prior art keywords
procedure
acid
mol
chlorobenzylsulfone
yield
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2001529435A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003511412A5 (enExample
JP2003511412A (ja
Inventor
シー．コゼンツァ スティーブン
レディー エム．ヴィ．ラマナ
レディー イー．プレムクマル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Temple Univ School of Medicine
Original Assignee
Temple Univ School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Temple Univ School of Medicine filed Critical Temple Univ School of Medicine
Publication of JP2003511412A publication Critical patent/JP2003511412A/ja
Publication of JP2003511412A5 publication Critical patent/JP2003511412A5/ja
Application granted granted Critical
Publication of JP4780885B2 publication Critical patent/JP4780885B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/10—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/18—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/02—Ortho- or ortho- and peri-condensed systems
    • C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
    • C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
    • C07C2603/24—Anthracenes; Hydrogenated anthracenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
JP2001529435A 1999-10-12 2000-10-11 正常細胞を化学療法剤の細胞毒性から保護するための方法 Expired - Lifetime JP4780885B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15912399P 1999-10-12 1999-10-12
US60/159,123 1999-10-12
PCT/US2000/028250 WO2001026645A1 (en) 1999-10-12 2000-10-11 Method for protecting normal cells from cytotoxicity of chemotherapeutic agents

Publications (3)

Publication Number Publication Date
JP2003511412A JP2003511412A (ja) 2003-03-25
JP2003511412A5 JP2003511412A5 (enExample) 2007-11-22
JP4780885B2 true JP4780885B2 (ja) 2011-09-28

Family

ID=22571170

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001529435A Expired - Lifetime JP4780885B2 (ja) 1999-10-12 2000-10-11 正常細胞を化学療法剤の細胞毒性から保護するための方法

Country Status (8)

Country Link
EP (1) EP1223923B1 (enExample)
JP (1) JP4780885B2 (enExample)
AT (1) ATE462423T1 (enExample)
AU (1) AU780844B2 (enExample)
CA (1) CA2387539C (enExample)
DE (1) DE60044092D1 (enExample)
IL (1) IL149064A0 (enExample)
WO (1) WO2001026645A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548553B2 (en) 1997-10-03 2003-04-15 Temple University-Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents
CA2366750C (en) * 1999-04-02 2010-06-01 Temple University - Of The Commonwealth System Of Higher Education (e)-styryl sulfone anticancer agents
US6541475B2 (en) * 2000-04-14 2003-04-01 Temple University - Of The Commonwealth System Of Higher Education α, β-unsaturated sulfones for treating proliferative disorders
US6486210B2 (en) * 2000-04-14 2002-11-26 Temple University—Of the Commonwealth System of Higher Education Substituted styryl benzylsulfones for treating proliferative disorders
JP2004510761A (ja) 2000-10-05 2004-04-08 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 増殖性疾病を治療するための置換（ｅ）−スチリルベンジルスルホン
US6833480B2 (en) 2001-02-27 2004-12-21 Temple University - Of The Commonwealth System Of Higher Education (Z)-styrylbenzylsulfones and pharmaceutical uses thereof
WO2002069892A2 (en) * 2001-02-28 2002-09-12 Temple University Of The Commonwealth System Of Higher Education METHOD FOR PROTECTING CELLS AND TISSUES FROM IONIZING RADIATION TOXICITY WITH α, β UNSATURATED ARYL SULFONES
ES2373945T3 (es) * 2002-02-28 2012-02-10 Temple University - Of The Commonwealth System Of Higher Education Bencilsulfonas de (e)-2,6-dialcoxiestirilo amino sustituido sustituidas en 4 para tratar trastornos proliferativos.
CA2546495C (en) * 2003-11-14 2012-10-09 Temple University - Of The Commonwealth System Of Higher Education Alpha, beta-unsaturated sulfoxides for treating proliferative disorders
NZ565561A (en) * 2005-07-29 2011-01-28 Onconova Therapeutics Inc Formulation of radioprotective alpha, beta unsaturated aryl sulfones
EP2091527B1 (en) * 2006-12-13 2016-03-23 Temple University - Of The Commonwealth System of Higher Education Sulfide, sulfoxide and sulfone chalcone analogues, derivatives thereof and therapeutic uses thereof
CN118239868A (zh) * 2019-07-18 2024-06-25 华夏生生药业(北京)有限公司 氨基甲酸酯取代的苯乙烯基砜类化合物及其制备方法和用途
CN111253935B (zh) * 2019-12-24 2022-12-13 安徽大学 一种双通道检测极性和粘度的双光子荧光探针及其制备方法和用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517429A (ja) * 1990-01-23 1993-01-26 Ciba Geigy Ag 殺微生物剤組成物
WO1996040629A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
WO1998006391A1 (en) * 1996-08-14 1998-02-19 Mor-Research Applications Ltd. Pharmaceutical compositions comprising tyrphostins
WO1999018068A1 (en) * 1997-10-03 1999-04-15 Temple University - Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT93772A (pt) * 1989-04-17 1991-01-08 Searle & Co Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0517429A (ja) * 1990-01-23 1993-01-26 Ciba Geigy Ag 殺微生物剤組成物
WO1996040629A1 (en) * 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
WO1998006391A1 (en) * 1996-08-14 1998-02-19 Mor-Research Applications Ltd. Pharmaceutical compositions comprising tyrphostins
WO1999018068A1 (en) * 1997-10-03 1999-04-15 Temple University - Of The Commonwealth System Of Higher Education Styryl sulfone anticancer agents

Also Published As

Publication number Publication date
ATE462423T1 (de) 2010-04-15
DE60044092D1 (de) 2010-05-12
AU1198901A (en) 2001-04-23
CA2387539C (en) 2010-09-21
IL149064A0 (en) 2002-11-10
EP1223923A1 (en) 2002-07-24
AU780844B2 (en) 2005-04-21
EP1223923A4 (en) 2007-09-05
WO2001026645A1 (en) 2001-04-19
EP1223923B1 (en) 2010-03-31
CA2387539A1 (en) 2001-04-19
JP2003511412A (ja) 2003-03-25

Similar Documents

Publication Publication Date Title
US6767926B1 (en) Method for protecting normal cells from cytotoxicity of chemotherapeutic agents
JP4780885B2 (ja) 正常細胞を化学療法剤の細胞毒性から保護するための方法
AU774362B2 (en) Lipoic acid derivatives and their use in treatment of disease
TWI430796B (zh) 端粒酶活化化合物及其使用方法
JP6162133B2 (ja) 潰瘍性大腸炎を抑制するプロトベルベリン生物学的アルカロイド誘導体およびその使用
JPH06506227A (ja) ５α−リダクターゼ阻害剤および抗アンドロゲン剤を含む前立腺過形成を治療するための併用薬剤組成物
IL284397B1 (en) Compositions and methods for regulating hair growth
KR20140147619A (ko) 신규한 칼콘 유도체 및 이의 용도
JP2015526396A (ja) 置換トロポロン誘導体およびその使用方法
JP5278968B2 (ja) 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
JP2003530433A (ja) 増殖性障害を治療するための置換スチリルベンジルスルホン
NZ517069A (en) New stilbenes with vascular damaging activity
JP2009527479A (ja) ヒドロキシピペリジン誘導体とその使用
JP4162994B2 (ja) 諸疾患状態の処置のための薬物に使用する化合物とその製造方法
CA1330446C (en) Phenolic thioalkylamides as inhibitors of 5-lipoxygenase
ES3017557T3 (en) Cytotoxic compounds inhibiting tubulin polymerisation
JP2004510761A (ja) 増殖性疾病を治療するための置換（ｅ）−スチリルベンジルスルホン
FR3046416A1 (fr) Composes " multi-cibles " a activite inhibitrice des histone-desacetylases et de la polymerisation de la tubuline pour son utilisation dans le traitement du cancer
JP2004521126A (ja) （ｚ）−スチリルベンジルスルホン及びそれらの医薬としての使用
CN115703727B (zh) 一种过硫化氢前药及其制药用途
US5002967A (en) Phenolic thioethers, sulfoxides, and disulfides as inhibitors of 5-lipoxygenase
US20030004192A1 (en) Method of modulating NF-kB activity
US4835190A (en) Phenolic thioethers as inhbitors of 5-lipoxygenase
JP2840337B2 (ja) 腫瘍転移抑制剤
CA2888379A1 (fr) Composes 3,4-bis(catechol)pyrrole-n-substitues, leur preparation et utilisation dans le traitement du cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110526

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20110526

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110628

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110705

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140715

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4780885

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250